08:05 AM EDT, 09/11/2024 (MT Newswires) -- TFF Pharmaceuticals ( TFFP ) said Wednesday that it has partnered with Emory University and the US Biomedical Advanced Research and Development Authority, or BARDA, to test the possibility of converting Emory's antiviral against influenza and COVID into a dry powder for inhalation.

Financial terms were not disclosed.

TFF said the contract supports early-stage therapeutic platform development under BARDA's Flexible and Strategic Therapeutic program.

The company said powderizing the mRNA-based treatment improves the stability of the drug and eliminates the need for cold-chain storage.

Price: 1.9400, Change: -0.06, Percent Change: -3.00